LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

NVO

112.01

-0.39%↓

JNJ

160.15

-0.86%↓

ABBV

189.51

-0.07%↓

LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

NVO

112.01

-0.39%↓

JNJ

160.15

-0.86%↓

ABBV

189.51

-0.07%↓

LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

NVO

112.01

-0.39%↓

JNJ

160.15

-0.86%↓

ABBV

189.51

-0.07%↓

LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

NVO

112.01

-0.39%↓

JNJ

160.15

-0.86%↓

ABBV

189.51

-0.07%↓

LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

NVO

112.01

-0.39%↓

JNJ

160.15

-0.86%↓

ABBV

189.51

-0.07%↓

Kodu・Aktsiate loetelu・Merck & Co Inc.

Merck & Co Inc.

Suletud

Sektor Tervishoid

103.73 -0.47

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

103.7

Max

105.05

Põhinäitajad
By Trading Economics
Sissetulek	693M 5.5B
Müük	310M 16B
P/E Sektori keskmine	137.56 112.16
Aktsiakasum	2.28
Kasumimarginaal	33.861
Töötajad	72,000
EBITDA	491M 7.4B

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+31.51 upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	31. okt 2024
Järgmine dividendimakse kuupäev	6. jaan 2025
Järgmine aktsia dividendi kuupäev (ex-date)	12. dets 2024

Turustatistika
By TradingEconomics
Turukapital	-9.4B 278B
Eelmine avamishind	104.2
Eelmine sulgemishind	103.73

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

103.86 / 109.69 Toetus ja vastupanu

Merck & Co Inc. Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

23. okt 2024, 14:04 UTC

Omandamised, ülevõtmised, äriostud

Merck Buys Yale Cancer-Therapy Spinout Modifi Biosciences

9. aug 2024, 11:14 UTC

Omandamised, ülevõtmised, äriostud

Merck Buying Drug Targeting B-Cell Diseases for Up to $1.3 Billion

30. juuli 2024, 14:00 UTC

Tulu

Trending: Merck 2Q Profit Beats Expectations; Fiscal Year Adjusted EPS Outlook Lowered

30. juuli 2024, 11:17 UTC

Tulu

Merck Swings to 2Q Profit Ahead of Views, Lowers FY24 Adjusted EPS Outlook

24. okt 2024, 13:50 UTC

Omandamised, ülevõtmised, äriostud

This Biotech Stock Could Rocket 800%, Analyst Says -- Barrons.com

3. okt 2024, 19:02 UTC

Omandamised, ülevõtmised, äriostud

CEOs Are on the Hunt for More M&A. Where the Next Deals Are. -- Barrons.com

3. okt 2024, 18:20 UTC

Omandamised, ülevõtmised, äriostud

CEOs Are on the Hunt for More M&A. Where the Next Deals Are. -- Barrons.com

1. okt 2024, 10:46 UTC

Omandamised, ülevõtmised, äriostud

Merck to Post 3Q Charge of About 28c/Share on Curon Deal >MRK

1. okt 2024, 10:46 UTC

Omandamised, ülevõtmised, äriostud

Merck Completes Acquisition of Investigational B-Cell Depletion Therapy, CN201, From Curon Biopharmaceutical

30. sept 2024, 21:02 UTC

Peamised uudised

FOMO on China Stock Rally? Think Twice About Buying In. -- Barrons.com

12. sept 2024, 15:02 UTC

Peamised uudised

Moderna Cost Cuts Fail to Restore Investor Trust -- Heard on the Street -- WSJ

12. sept 2024, 10:00 UTC

Peamised uudised

Moderna Pulls Back on R&D and Delays Timeline for Profitability -- Barrons.com

9. sept 2024, 17:55 UTC

Peamised uudised

A Better Drug Than Merck's Blockbuster Keytruda? Not So Fast -- WSJ

9. sept 2024, 09:17 UTC

Peamised uudised

Merck Stock Falls After Rival Beats Keytruda Cancer Drug in Trial -- Barrons.com

3. sept 2024, 17:22 UTC

Peamised uudised

Pfizer Better Watch Out for This Biotech -- Heard on the Street-- WSJ

12. aug 2024, 14:30 UTC

Omandamised, ülevõtmised, äriostud

Correction to Big Drugmakers Are Clinching Smaller Deals Article -- WSJ

12. aug 2024, 09:30 UTC

Peamised uudised

Omandamised, ülevõtmised, äriostud

Big Drugmakers Are Clinching Smaller Deals -- WSJ

1. aug 2024, 15:56 UTC

Tulu

Merck Created the World's Biggest Drug. Now It -2-

1. aug 2024, 15:56 UTC

Tulu

Merck Created the World's Biggest Drug. Now It Has to Replace It. -- Barrons.com

30. juuli 2024, 15:53 UTC

Tulu

Nasdaq Dives As Microsoft Earnings Loom; Two Dow Jones Leaders Crater On Earnings (Live Updates) -- IBD

30. juuli 2024, 15:28 UTC

Market Talk

Tulu

Merck's Keytruda Continues to See Growth in U.S., Abroad -- Market Talk

30. juuli 2024, 13:45 UTC

Tulu

Trending: Merck 2Q Profit Beats Expectations; FY Adj EPS Outlook Lowered

30. juuli 2024, 10:45 UTC

Tulu

Merck Beats Profit And Sales Expectations Amid Keytruda Strength, But Provides Mixed Full-Year Outlook -- MarketWatch

30. juuli 2024, 10:32 UTC

Tulu

Merck Revised 2024 Adjusted EPS View Includes 51c/Share Charge on EyeBio Deal >MRK

30. juuli 2024, 10:31 UTC

Tulu

Merck 2Q Sales Rose 11% Ex-Forex >MRK

30. juuli 2024, 10:31 UTC

Tulu

Merck Posts Stronger-Than-Expected Results, But Outlook Falls Short -- IBD

30. juuli 2024, 10:30 UTC

Tulu

Merck 2Q Keytruda Sales Up 16% >MRK

30. juuli 2024, 10:30 UTC

Tulu

Merck 2Q Pharmaceutical Sales $14.41B >MRK

30. juuli 2024, 10:30 UTC

Tulu

Merck 2Q Keytruda Sales $7.27B >MRK

30. juuli 2024, 10:30 UTC

Tulu

Merck 2Q Gardasil/Gardasil 9 Sales Up 1% >MRK

Võrdlus sarnastega

Hinnamuutus

Merck & Co Inc. Prognoos

Hinnasiht

By TipRanks

31.51% tõus

12 kuu keskmine prognoos

Keskmine 137.07 USD 31.51%

Kõrge 155 USD

Madal 115 USD

Põhineb 20 Wall Streeti analüütiku instrumendi Merck & Co Inc. 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

20 ratings

Osta

Hoia

Müü

Põhineb 20 analüütiku instrumendi Merck & Co Inc. aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

103.86 / 109.69Toetus ja vastupanu

All events are bearish.

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

Sentiment

By Acuity

94 / 389 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Merck & Co Inc.

Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through two segments: Pharmaceutical and Animal Health. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products. Its human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations. The Animal Health segment develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species.